Journal of Shanghai Jiao Tong University (Medical Science) >

2022 , Vol. 42 >Issue 12: 1745 - 1750

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.12.013

Review

Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19

  • Yutang ZHANG ,
  • Yijie JIN ,
  • Fengchun ZHANG ,
  • Yingchun XU
Expand
  • 1.Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215127, China
XU Yingchun, E-mail: xiaoxu2384@163.com.

Received date: 2022-06-24

  Accepted date: 2022-09-04

  Online published: 2022-12-28

Supported by

National Natural Science Foundation of China(81301858);Suzhou Science and Technology Project(SYS201404);Natural Science Foundation of Jiangsu Province(BK20181186)

Fold

Abstract

Coronavirus disease 2019 (COVID-19) has become a major global public health event as a new acute respiratory infectious disease. During the COVID-19 pandemic, compared with the healthy population, cancer patients had a higher risk of developing comorbidities of other systems, due to their bad poor immunity and older age. Research showed that breast cancer, as a malignant disease, had the highest disease incidence in female patients. Breast cancer patients with COVID-19 infection often have worse prognosis, and they have to postpone anti-tumor treatment due to COVID-19 infection. At present, the effect of delayed treatment on the survival rate of breast cancer patients is unclear, and whether the treatment plan of these patients should be adjusted is still being studied. Through the systematic review of existing clinical research studies, the guidelines of various societies and the expert consensus, this paper reviews the selection and rationalization of breast cancer treatment options under the COVID-19 epidemic, and discusses the opportunity and approaches of anti-tumor treatment for breast cancer patients infected with COVID-19.

Key words： breast cancer; coronavirus disease 2019 (COVID-19); surgery; radiotherapy; systemic therapy

Cite this article

Yutang ZHANG , Yijie JIN , Fengchun ZHANG , Yingchun XU . Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(12) : 1745 -1750 . DOI: 10.3969/j.issn.1674-8115.2022.12.013

References

1 LIANG W H, GUAN W J, CHEN R C, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21(3): 335-337.
2 TIAN J, YUAN X, XIAO J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre,
3 YU J, OUYANG W, CHUA M L K, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China[J]. JAMA Oncol, 2020, 6(7): 1108-1110.
4 ZHANG L, ZHU F, XIE L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China[J]. Ann Oncol, 2020, 31(7): 894-901.
5 DAI M Y, LIU D B, LIU M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak[J]. Cancer Discov, 2020, 10(6): 783-791.
6 FOX T A, TROY-BARNES E, KIRKWOOD A A, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo-or immunotherapy[J]. Br J Haematol, 2020, 191(2): 194-206.
7 LEE L Y, CAZIER J B, ANGELIS V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study[J]. Lancet, 2020, 395(10241): 1919-1926.
8 PATHANIA A S, PRATHIPATI P, ABDUL B A, et al. COVID-19 and cancer comorbidity: therapeutic opportunities and challenges[J]. Theranostics, 2021, 11(2): 731-753.
9 JEE J, FOOTE M B, LUMISH M, et al. Chemotherapy and COVID-19 outcomes in patients with cancer[J]. J Clin Oncol, 2020, 38(30): 3538-3546.
10 ROBILOTTI E V, BABADY N E, MEAD P A, et al. Determinants of COVID-19 disease severity in patients with cancer[J]. Nat Med, 2020, 26(8): 1218-1223.
11 DE AZAMBUJA E, TRAPANI D, LOIBL S, et al. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer[J]. ESMO Open, 2020, 5(Suppl 3): e000793.
12 黎立喜, 马飞. 《新型冠状病毒肺炎疫情期间乳腺癌合理化诊疗指南》解读[J]. 中国肿瘤临床, 2020, 47(8): 379-383.
12 LI L X, MA F. Interpretation of guidelines for the diagnosis and treatment of breast cancer during the COVID-19 outbreak[J]. Chin J Clin Oncol, 2020, 47(8): 379-383.
13 MARTA G N, POORTMANS P. Moderately hypofractionated breast radiation therapy: is more evidence needed? [J]. Lancet Oncol, 2019, 20(5): e226.
14 GRADISHAR W J, ANDERSON B O, ABRAHAM J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(4): 452-478.
15 WANG S L, FANG H, SONG Y W, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(3): 352-360.
16 CURIGLIANO G, BANERJEE S, CERVANTES A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus[J]. Ann Oncol, 2020, 31(10): 1320-1335.
17 SULLIVAN R J, JOHNSON D B, RINI B I, et al. COVID-19 and immune checkpoint inhibitors: initial considerations[J]. J Immunother Cancer, 2020, 8(1): e000933.
18 DEEKS J J, DINNES J, TAKWOINGI Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2[J]. Cochrane Database Syst Rev, 2020, 6(6): CD013652.
19 VAN KAMPEN J J A, VAN DE VIJVER D A M C, FRAAIJ P L A, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)[J]. Nat Commun, 2021, 12(1): 267.
20 RHEE C, KANJILAL S, BAKER M, et al. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? [J]. Clin Infect Dis, 2021, 72(8): 1467-1474.
21 BULLARD J, DUST K, FUNK D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples[J]. Clin Infect Dis, 2020, 71(10): 2663-2666.
22 YU K D, FAN L, QIU L X, et al. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent[J]. Oncotarget, 2017, 8(28): 46549-46556.
23 胡夕春, 胡志皇, 王碧芸, 等. 新型冠状病毒肺炎与抗肿瘤药物治疗[J]. 中国癌症杂志, 2022, 32(6): 499-511.
23 HU X C, HU Z H, WANG B Y, et al. COVID-19 and systemic anti-cancer therapy[J]. Chin Oncol, 2022, 32(6): 499-511.
24 WEI J L, WU M J, LIU J, et al. Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: a multi-center retrospective study in Hubei, China[J]. Breast, 2021, 59: 102-109.
25 BERSANELLI M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors[J]. Immunotherapy, 2020, 12(5): 269-273.
26 WU Q J, CHU Q, ZHANG H Y, et al. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors[J]. Cancer Commun (Lond), 2020, 40(8): 374-379.
27 LUO J, RIZVI H, EGGER J V, et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers[J]. Cancer Discov, 2020, 10(8): 1121-1128.
28 LIèVRE A, TURPIN A, RAY-COQUARD I, et al. Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19)[J]. Eur J Cancer, 2020, 141: 62-81.
29 WANG B, HUANG Y. Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis[J]. Oncoimmunology, 2020, 9(1): 1824646.
30 DI GIACOMO A M, GAMBALE E, MONTERISI S, et al. SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: clinical course and outcome[J]. Eur J Cancer, 2020, 133: 1-3.
31 HU S Y, YIN F Y, NIE L T, et al. Estrogen and estrogen receptor modulators: potential therapeutic strategies for COVID-19 and breast cancer[J]. Front Endocrinol (Lausanne), 2022, 13: 829879.
32 SAINI K S, LANZA C, ROMANO M, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy[J]. Br J Cancer, 2020, 123(5): 694-697.
Options
Outlines

/

〈 〉